Company Overview and News
VANCOUVER, British Columbia, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Coro Mining Corp. (“Coro” or the “Company”) (TSX: COP) is pleased to update shareholders that its strategy to focus on its large Marimaca exploration project has taken another step forward following a decision by its owners to place the smaller SCM Berta operation on care and maintenance.
CROJF COP APR APRLY
VANCOUVER, British Columbia, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Coro Mining Corp. (“Coro” or the “Company”) (TSX: COP) is pleased to announce today the successful closing of its rights offering following the expiry of the issued rights on September 20, 2018. The Company issued a total of 671,591,957 common shares in the rights offering for gross proceeds of approximately C$33.6 million. Combined with the non-brokered premium placement for C$13.
VANCOUVER, British Columbia, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Coro Mining Corp. (“Coro” or the “Company”) (TSX: COP) is pleased to announce that it has now completed the Chilean legal registrations and has title over 51% of the corporate entity holding the Marimaca 1-23 Claims, following the completion of the initial Definitive Feasibility Study, released in June 2018. This marks the first step in ownership over Marimaca.
2018-08-20 reuters - 1
Aug 20 (Reuters) - Canada’s main stock index rose on Monday as rising metal prices led to gains in material stocks, with hopes of resolution in the U.S.-China trade dispute boosting the sentiment.
NGD ABX CROJF ACBFF NGDAF K COP NGD CGC TWMJF ACB KGC CNQ WEED FQVLF FQM ABX
VANCOUVER, British Columbia, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Coro Mining Corp. (“Coro” or the “Company”) (TSX: COP) announces today a CAD 46.7 million (approximately US$36 million) financing plan, comprising of a closed premium non-brokered CAD 13.2 million (approximately US$10 million) private placement (“Private Placement”) with an entity of the Tembo Capital private equity group (“Tembo Capital”) and a forthcoming
VANCOUVER, British Columbia, July 24, 2018 (GLOBE NEWSWIRE) -- Coro Mining Corp. (“Coro” or the “Company”) (TSX:COP) announces that Alan Stephens, one of the founders of the Company, will step back from his responsibilities as Executive Director of Exploration effective July 31, 2018. He has accepted the invitation of the Board to become a Non-Executive Director and has also agreed a renewable 12-month consultancy agreement so that his skills and experience can be retained as the Company seeks to advance exploration at its flagship Marimaca asset.
VANCOUVER, British Columbia, June 28, 2018 (GLOBE NEWSWIRE) -- Coro Mining Corp. (“Coro” or the “Company”) (TSX:COP) is pleased to announce that the Environmental Assessment Commission of Antofagasta, Chile has approved the Environmental Impact Declaration (DIA) for the Marimaca Phase 1 Project.
VANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) -- Coro Mining Corp. (TSX:COP) (“Coro”, the “Company”) is pleased to report that all of its incumbent directors were re-elected at its annual general and special meeting of shareholders held in Vancouver, British Columbia, on Wednesday, June 27, 2018 (the “Meeting”). Below are the detailed results of the votes received by proxy and voted at the Meeting on the election of the Company’s directors.
VANCOUVER, British Columbia, June 22, 2018 (GLOBE NEWSWIRE) -- Coro Mining Corp. (“Coro” or the “Company”) (TSX:COP) is pleased to announce that the Definitive Feasibility Study (DFS) completed by Coro as a condition of its earn in to acquire up to a 75% interest in the Marimaca 1-23 Claim (“the Project”), located near Antofagasta, Chile has confirmed the technical and economic viability of developing the Project.
CROJF MALRY COP MALRF MIN
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:COP / Coro Mining Corp. on message board site Silicon Investor.